BioNexus Gene Lab Corporation (BGLC)

Obviously don't trade them all just a couple 

You must be really rich. Trading 20 stocks a day a making so much profit on every trade in pre market.

Well my stops work well I use my middle finger and price alerts premarket and aftermarket  but there might be some newbies that think it's a brokerage allows it or do not have a sophisticated program setup ..
If you need fully automated stop-loss execution in extended hours, confirm with your broker or consider using advanced trading software that integrates with your brokerage’s API for custom order logic

Stops don’t work pre or after market

Stop out at 6.30 now another quick flip

$4.50s in some

What's the OS here? Ya think maybe a week or 2 for this one? Maybe longer....looks like low floater as they say... Are there specific dates as catalysts for upside?

Out yesterday.

Monday or Tuesday will be my last day here if no news or stop loss gets triggered.

$4.80 average, have a stop loss place at $4.70 if it triggers I am out and not looking back.

Thanks dino I got some of both!
Playing with pstv while waiting for tglo.
BGLC

Next week or two will be the go time for BGLC. Someone has been loading on quiet days.

Waiting on news to blow it out of the park in the teens, take a look at $NEUP too news is due early 4th quarter, also very low float MERK also owns shares including the largest institutional and assets under management in the World is top holder, enough funds to last them in the end of next year, its a screaming buy hands over fist, watch the news, but I have a feeling it will hit the 20's before news, people are waiting and buying slowly.

Got some!
BGLC

This is going to pop hard soon, not sure when, but it will pop into the teens.

Getting ready to pop hard.

Could pop again in the short term😇

BGLC.....................................................................p/m

BioNexus Gene Lab Corp. and Fidelion Diagnostics Announce Landmark Alliance—Touted as a new “DeepSeek Moment” in Precision Oncology
KUALA LUMPUR, Malaysia, July 30, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (“BGLC”, Nasdaq:?BGLC) and Fidelion?Diagnostics?Pte?Ltd, a Singaporean company (“Fidelion”) today announced the signing of a term sheet for a strategic, cross-equity partnership that the parties are calling a “DeepSeek-class leap” for liquid biopsy cancer monitoring and AI-driven biotechnology. This builds on BGLC’s mission to be a global leader in liquid biopsies, and tumor naïve oncology solutions.

Under the term sheet, BGLC will acquire a strategic equity stake in Fidelion and secure exclusive commercial rights to Fidelion’s VitaGuard™ minimal-residual-disease (MRD) platform across Southeast?Asia (ASEAN). Fidelion, in turn, will receive an equity investment from BGLC together with a licence fee, aligning both companies for long-term shared value creation. The transaction is subject to the execution of definitive agreements by the parties.

What’s a Liquid Biopsy?
A simple blood draw that looks for fragments of tumour DNA (called ctDNA) circulating in the bloodstream. No scalpel, no hospital stay.

Why it Matters:
*?Earlier warning. Cancer recurrence can be detected months before it shows up on a CT scan.
*?Less hassle. One tube of blood vs. invasive tissue re-biopsies.
*?Lower cost. Labs can now run VitaGuard™ tests for under USD?$300, vs. ~USD?$3,000 currently in the U.S.

Tumour-Naïve vs. Tumour-Informed:
Most ctDNA tests first need a slice of the original tumour (“tumour-informed”) to know what mutations to track. VitaGuard™ is tumour-naïve—it can spot the earliest traces of many cancers without prior tumour sequencing. It is similar in application to facial-recognition software for cancer except that it works even if it has never seen the face before.

Tongshu?Gene Biotechnology Co., Limited, a company based in China, is the original developer of VitaGuard™ and Fidelion is intended to be the licensing arm for the technology under an agreement to be completed by the parties. The VitaGuard™ system is already commercialised in China.

The transaction arrives amidst China’s biopharma sector posting major licensing deal-flow and billions in venture capital and IPO proceeds over the last 18?months, fuelling what analysts dub the “China-Biotech Wave.”

One of the key innovations of VitaGuard™ technology is that it can slash per-patient MRD monitoring cost from more than US?$3,000 to under US?$300 and is supported by numerous positive clinical studies in China. With Southeast Asia’s cancer incidence projected to top 2.4?million new cases annually by 2030, a sub-US?$300 test opens a multi-billion-dollar recurring market.

Sam?Tan, Chief Executive Officer of BGLC, said:
“This alliance is nothing short of a paradigm shift - the moment precision oncology gets its own “DeepSeek-class” technology upgrade. By combining VitaGuard™ with our commercial network, we will deliver next-generation cancer care to 680?million people across Southeast?Asia.”

Dr.?Yan?Linghua, Chief Executive Officer of Tongshu?Gene and Executive Director of Fidelion, added:
“Our team in China spent years perfecting VitaGuard’s one-tube, high-fidelity chemistry. Building Fidelion for global commercialisation—and partnering with BGLC for Southeast?Asia - creates the fastest possible path to scale. Together, we aim to shatter the cost-accuracy trade-off, bringing ultra-sensitive, AI-ready cancer surveillance to every clinic.”

Strategic Highlights

“DeepSeek-Class” Technology – VitaGuard™ achieves 0.02?% variant-allele-frequency sensitivity with 95% cfDNA recovery and 14-day room-temperature sample stability while compressing cost 4-10× versus legacy assays.
Market Access at Scale – BGLC will lead regulatory submissions and a phased roll-out beginning in Singapore and Malaysia, expanding rapidly through the rest of ASEAN.
Mutual Skin in the Game – Cross-shareholdings cement long-term strategic alignment.
Pipeline & AI Acceleration – The alliance contemplates joint development of companion-diagnostic programs and an AI-powered Cancer Interception System trained on VitaGuard™ longitudinal MRD datasets.
About Fidelion?Diagnostics Pte. Ltd.

Fidelion is a next-generation liquid-biopsy company with a mission to ignite the “DeepSeek Moment” in biotechnology. The company’s proprietary VitaGuard™ platform, originally developed by Tongshu?Gene in China, and to be assigned to Fidelion, couples ultra-efficient pre-analytical recovery with one-tube UMI chemistry to deliver industry-leading < 0.03?% LoD at a fraction of incumbent cost - precisely the high-fidelity data foundation required for AI-driven cancer interception.

About Tongshu?Gene Biotechnology Co., Limited

Tongshu?Gene, located in Wuxi, China, pioneered the core technology behind VitaGuard™, including its one-tube UMI workflow and dual DNA/RNA probing chemistry. Tongshu will remain Fidelion’s partner in manufacturing and R&D of the technology.

About BioNexus Gene Lab Corp.

BGLC is an innovation-led life-sciences platform – bringing together precision diagnostics, cross-border expertise, and AI data development. Listed on Nasdaq, BGLC’s mission is to make next-generation healthcare accessible, affordable, and actionable for every patient.

Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements regarding the completion of the proposed transaction, anticipated regulatory approvals, commercial launch plans, and the expected benefits of the partnership. Forward-looking statements are subject to risks and uncertainties tha

BGLC........................................................................weeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeee

Ok $12.45

BGLC....................................................................p/m

The Company’s previously reported one-for-ten (1-for-10) reverse stock split of its common stock became effective at 12:01 a.m. Eastern Time on April 7, 2025. The Company’s common stock begin trading on a split-adjusted basis on The Nasdaq Capital Market under the existing ticker symbol “BGLC” on that same day. Immediately prior to the reverse stock split, the Company had 17,967,663 shares of common stock issued and outstanding and immediately after the reverse stock split, the Company had 1,796,597 shares of common stock issued and outstanding.



No fractional shares were issued in connection with the reverse stock split. Instead, shareholders who would otherwise be entitled to receive a fractional share received a cash payment in lieu thereof based on the daily Volume Weighted Average Price (VWAP) of our common stock, calculated for the ten (10) trading days immediately preceding the effective date of the Reverse Stock Split, multiplied by the fractional share. Note that the forgoing statement corrects the cash payment price previously reported by the Company.



The Reverse Split was conducted as part of efforts by the Company to regain compliance with Nasdaq Rule 5550(a)(2) (“Minimum Bid Price Rule”) within the compliance period provided by Nasdaq, which was to regain compliance under this rule by May 1, 2025.

BGLC.....................................weeeeeeeeeeeeeeeeeeeeeeeeeeeee

BGLC.....................................................https://stockcharts.com/h-sc/ui?s=BGLC&p=W&b=5&g=0&id=p86431144783

bglc....................................https://stockcharts.com/h-sc/ui?s=bglc&p=W&b=5&g=0&id=p86431144783

Run low floater run .54

BGLC...............................https://stockcharts.com/h-sc/ui?s=BGLC&p=W&b=5&g=0&id=p86431144783

BGLC........................weeeeeeeeeeeeeeeeeeeeeeeeeeeeeee

BGLC: Well then, a monster CONGRATS to yah, (haughty) Admiral T-F-C-D, Dude!!!!

pic.twitter.com/7LxK0eedCj— THE FINAL COUNTDOWN (@THIS_TIME_X) January 2, 2025

bglc.......................https://stockcharts.com/h-sc/ui?s=BGLC&p=W&b=5&g=0&id=p86431144783

BioNexus Gene Lab Corp. Signs Strategic Partnership MOU with Shenzhen Rongguang Group to Advance Cancer Screening, Precision Medicine, and Preventative Healthcare Solutions

BioNexus Gene Lab Corp Announces New Business Developments for Subsidiary Chemrex with Investment in High-Quality Color Paste Production

BioNexus Gene Lab Corp. Completes Strategic RM 1 Million Investment in Ascension Innovation Sdn Bhd

BioNexus Gene Lab Corp. Agrees to Invest RM 1.2 million in Ascension Innovation (AISB) to Advance Digital Health Innovation through AI adoption in Healthcare

.73 news out

BGLC loss only .02/share, Revenue 11 Million dollars, Market cap 11 Million dollars. May be time to buy the dips here

BGLC..............................https://stockcharts.com/h-sc/ui?s=BGLC&p=W&b=5&g=0&id=p86431144783

A new theory that makes sense to me is hedge funds battling each other. Big Money HF-Bears get caught in a bear trap by big money HF-bear trappers (Aka Bulls).

Retail does not have the fire power for the shenanigans we saw here recently. This one could be overseas Asian money teaching Goldmansucks-a-lot bears some new zoo tricks?

Check this out:

https://www.sec.gov/comments/s7-29-22/s72922-20153799-321641.pdf

LMAO. too funny. Parrots-Are-Us propagating the official nonsense and lies.

No one is fooled

Shorts got their arses handed to them this week on BGLC

He made some really good points about the obvious action that's been going on for some time now, with a certain group of individuals are cornering and targeted certain stocks at certain times, it would be highly unlikely its just a bunch of boiler room day trader types from over seas or who knows from where, there is too much of an organized effect to controlling the volume upticks and price ranges, it smells like there is some sort of professional elements of it all, the way it's carried out, to create many others to join into the action, which is most likely part of their plan,as they cash out of it after they front ran it probably from the day before,and then short them at the day highs, and profit from that as well, it reeks of coming from those with insider info about them on the professional level before they run, a bunch of retail pumpers organizing a pump are highly unlikely to enough capital between them to run these kind of moves, it comes across like a bunch of rogue professionals got together to pull it off, and mostly in place over seas where they can get away with it, the SEC here couldn't shoot the broadside of a barn with a machine gun, their heads are so far up their butts, for them to take noticed, or perhaps they have,and won't do anything about it, because in the end, probably connected to their friends on the W Street, and that's who they really work for,or want to work in their future,

I agree. I don't trade, haven't for years. But I saw this post https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173832935, noting the big price movement on a couple other Q listed stocks today and had to check them out. I see this one has had two big reverse splits..... it can happen, even with real companies.

I noted that there's lots of debt...and some sales. But when they massive one day pops occur, there's gotta be reasons....,and buckey had some words on it

Why would anyone want to own one of those worthless piece of trash grays listed stocks, run by OTC scamming criminals in the first place,and then pump for no other other reason so they could dump their worthless shares onto someone else.

EgoMikey will never listen to reason...... got his head handed to him by a number of us for his blatant pumping of NWGC.

I have no respect for such low life pumper scum

Today, Capt. TIM!!! That "Joby-Numb-Nuts-Ka-Nobody" is a PIECE OF SHIT!!! (And I'm GLAD I'm out for good from that HAUGHTY Orions Baloney Club.)

WHEN DID THAT HAPPEN?

FINRA aggregates and reports the short positions the brokers provide to them. The SEC aggregates and reports the failure to deliver information the brokers report to them. It isn't lies, it's the facts. The lies are the con artist pumpers who use "shorty" as an excuse to explain the inevitable decline in share price when they sell their holdings.

LOL, sure, and fairy pixel dust blew up the share volume again for round 2 at the prefect time learn the shorts a hard lesson.
Naked shorts just handed their asses again today. But keep parroting the official FINRA lies while congress writes the subpoena to demand an audit
of the last short disaster

It's all fun and games for them, they run the casino, if they got burned on a certain amount of naked short positions,they don't give a shtt about it, they made a boat load off of their games today selling stock to chasers, and shorting it to them in the run ups, with the huge volume they created,they know that their creating bag holders,and could care less about who they burn today,their machines will wipe out anyone who gets in their way.